Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial

环境管理计划 恩帕吉菲 医学 心力衰竭 内科学 心脏病学 能量代谢 随机对照试验 2型糖尿病 糖尿病 内分泌学 矿物学 电子探针 化学
作者
Moritz Hundertmark,Amanda Adler,Charalambos Antoniades,Ruth L. Coleman,Julian L. Griffin,Rury R. Holman,Hanan Lamlum,Jisoo Lee,Daniel Massey,Jack J. Miller,Joanne Milton,Shveta Monga,Ferenc E. Mózes,Areesha Nazeer,Betty Raman,Oliver J. Rider,Christopher T. Rodgers,Ladislav Valkovič,Eleanor Wicks,Masliza Mahmod
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:147 (22): 1654-1669 被引量:93
标识
DOI:10.1161/circulationaha.122.062021
摘要

Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness. Methods: EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated. Results: Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin – placebo], –0.25 [95% CI, –0.58 to 0.09]; P =0.14) or HFpEF (adjusted mean treatment difference, –0.16 [95% CI, –0.60 to 0.29]; P =0.47]. Likewise, there were no changes in PCr/ATP during dobutamine stress in HFrEF (adjusted mean treatment difference, –0.13 [95% CI, –0.35 to 0.09]; P =0.23) or HFpEF (adjusted mean treatment difference, –0.22 [95% CI, –0.66 to 0.23]; P =0.32). No changes in serum metabolomics or levels of circulating ketone bodies were observed. Conclusions: In patients with either HFrEF or HFpEF, treatment with 10 mg of empagliflozin once daily for 12 weeks did not improve cardiac energetics or change circulating serum metabolites associated with energy metabolism when compared with placebo. Based on our results, it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03332212.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被ydlfvya采纳,获得10
刚刚
刚刚
1秒前
琉璃完成签到,获得积分10
1秒前
1秒前
斯文败类的应助被呆萌的豌豆采纳,获得10
2秒前
秀丽二娘发布了新的文献求助10
3秒前
思源的应助被一只萨卡班采纳,获得10
4秒前
平淡南霜完成签到,获得积分10
4秒前
5秒前
5秒前
鸢尾发布了新的文献求助10
6秒前
酷波er的应助被唐璜采纳,获得10
6秒前
zclm发布了新的文献求助10
6秒前
7秒前
AXQ完成签到,获得积分10
7秒前
ne完成签到,获得积分10
7秒前
驼驼万岁发布了新的文献求助10
8秒前
8秒前
8秒前
mmmm完成签到,获得积分20
9秒前
科研通AI6.4的应助被long采纳,获得10
9秒前
kangkang完成签到,获得积分20
10秒前
10秒前
香香香发布了新的文献求助10
10秒前
典雅焦完成签到,获得积分10
11秒前
11秒前
JamesPei的应助被辉煌采纳,获得10
12秒前
忧心的曼凝的应助被www2采纳,获得10
13秒前
13秒前
思源的应助被科研通管家采纳,获得10
13秒前
852的应助被科研通管家采纳,获得10
13秒前
Hello的应助被科研通管家采纳,获得10
14秒前
orixero的应助被科研通管家采纳,获得10
14秒前
天天向上的应助被科研通管家采纳,获得10
14秒前
顾矜的应助被科研通管家采纳,获得10
14秒前
VDC的应助被LDX采纳,获得30
14秒前
Owen的应助被科研通管家采纳,获得10
14秒前
ding的应助被Lutras采纳,获得10
14秒前
田様的应助被科研通管家采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187748
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843288
捐赠科研通 7785628
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482000